Claims: STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
These are attributed source records, not independent verification of each assertion.
Complete claim record (JSON) · Original source
- title: STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more Source
- url: https://www.statnews.com/pharmalot/2026/09/02/uniqure-huntingtons-fda-novo-nordisk-investors-pharmalittle-newsletter/?utm_campaign=rss Source
- summary: Hello there again from STAT’s London outpost, with Andrew Joseph here filling in for Mr. Pharmalot. Typing that out, I just misspelled my own last name, so it does in fact appear to be Wednesday. Let’s just get to the headlines … The drug pricing deals the White House signed with drug companies this week might not amount to much, at least not immediately , STAT explains. That’s because they chiefly apply to Medicaid, which by law gets the lowest prices of any U.S. payer, while exempting companie… Source
- published: Wed, 02 Sep 2026 13:26:55 +0000 Source